Karen L. Price

发表

Bayesian modeling of retrospective time-to-pregnancy data with digit preference bias

John W. Seaman, Karen L. Price, J. Seaman, 2006, Math. Comput. Model..

Facilitated Prior Elicitation with the Wolfram CDF

Baoguang Han, Fanni Natanegara, David Kahle, 2016 .

Incorporation of individual‐patient data in network meta‐analysis for multiple continuous endpoints, with application to diabetes treatment

Bradley P Carlin, Haoda Fu, Hwanhee Hong, 2015, Statistics in medicine.

Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation

Bradley P Carlin, Guochen Song, Margaret Gamalo-Siebers, 2017, Pharmaceutical statistics.

Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.

Karen L. Price, W. Litchy, A. Vinik, 2005, Clinical therapeutics.

Selective PKC Beta Inhibition with Ruboxistaurin and Endothelial Function in Type-2 Diabetes Mellitus

Karen L. Price, M. Reilly, E. Mohler, 2009, Cardiovascular Drugs and Therapy.

Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy

Karen L. Price, W. Litchy, A. Vinik, 2005, Muscle & nerve.

Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.

Karen L. Price, J. McGill, G. King, 2006, Expert opinion on drug safety.

First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19

Karen L. Price, M. Mulligan, N. Rouphael, 2021, Clinical pharmacology and therapeutics.

PMS2 The Efficacy of Duloxetine, Non-Steroidal Anti-Inflammatory Drugs, and Opioids in Osteoarthritis: A Meta-Analysis

Karen L. Price, M. Happich, B. Han, 2012 .

Innovative clinical trial design and delivery: a phase 3 COVID-19 post-exposure prophylaxis study in skilled nursing and assisted living facilities (BLAZE-2)

Karen L. Price, Lei-Bin Shen, J. Tuttle, 2021, Trials.

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Karen L. Price, A. Perelson, R. Ribeiro, 2022, Nature Communications.

The Practice of Prior Elicitation

John W. Seaman, Timothy H. Montague, Karen L. Price, 2019, Bayesian Applications in Pharmaceutical Development.

Inference and Decision Making for 21st-Century Drug Development and Approval

Frank E. Harrell, Carl Peck, Stephen J. Ruberg, 2019, The American Statistician.

Bayesian methods for design and analysis of safety trials

David Madigan, David Manner, H Amy Xia, 2014, Pharmaceutical statistics.

Guidance on the implementation and reporting of a drug safety Bayesian network meta‐analysis

Bradley P Carlin, Haoda Fu, Jouni Kerman, 2014, Pharmaceutical statistics.

Identifying Potential Adverse Events Dose-Response Relationships Via Bayesian Indirect and Mixed Treatment Comparison Models

Karen L. Price, S. Ruberg, H. Fu, 2013, Journal of biopharmaceutical statistics.

Correlation of vibratory quantitative sensory testing and nerve conduction studies in patients with diabetes

Karen L Price, Karen L. Price, M. Jimenez, 2007, Muscle & nerve.

Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease

Karen L. Price, E. Siemers, J. Cummings, 2015, Journal of Alzheimer's disease : JAD.

Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia.

Karen L. Price, E. Siemers, J. Cummings, 2014, Journal of Alzheimer's disease : JAD.

Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy.

Karen L Price, Karen L. Price, E. Bastyr, 2005, Clinical therapeutics.

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.

Karen L. Price, J. Ramirez, D. Skovronsky, 2021, JAMA.

Bayesian modeling of cost‐effectiveness studies with unmeasured confounding: a simulation study

Douglas Faries, John W Seaman, James D Stamey, 2014, Pharmaceutical statistics.

The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis

Karen L. Price, M. Happich, B. Han, 2014, BMC Musculoskeletal Disorders.

Comparison of Bayesian and Frequentist Meta-Analytical Approaches for Analyzing Time to Event Data

John W Seaman, James D Stamey, Karen L Price, 2013, Journal of biopharmaceutical statistics.

Clinical safety of the selective PKC-β inhibitor, ruboxistaurin

Karen L. Price, J. McGill, G. King, 2006 .

Evaluating the impact of unmeasured confounding with internal validation data: an example cost evaluation in type 2 diabetes.

Karen Price, John W. Seaman, Douglas Faries, 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation

Karen L. Price, R. Tiwari, Simin K. Baygani, 2017, Pharmaceutical statistics.

Statistical Considerations in Pediatric Cancer Trials: Report of American Statistical Association Biopharmaceutical Section Open Forum Discussions

Karen L. Price, Olga V. Marchenko, A. Naranjo, 2023, Statistics in Biopharmaceutical Research.